Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06834074 | Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors(NVL-655-EAP) | available | — | — | Nuvalent Inc.INDUSTRY | 12 | Sep 21, 2026 | clinicaltrials |
| NCT06797362 | Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors | available | — | — | Nuvalent Inc.INDUSTRY | 10 | Aug 25, 2026 |
| clinicaltrials |
| NCT06761976 | Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation | available | — | — | BayerINDUSTRY | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07601399 | An EAP Treatment Protocol of Zipalertinib | available | — | — | Taiho Oncology, Inc.INDUSTRY | 0 | Jun 11, 2026 | clinicaltrials |
| NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | available | — | — | xCuresINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval | available | — | — | Agenus Inc.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT06872489 | Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors | available | — | — | Second Life TherapeuticsINDUSTRY | 0 | Jul 23, 2025 | clinicaltrials |
| NCT04146571 | Expanded Access to Ensartinib for Participants With ALK+ NSCLC | available | — | — | Xcovery Holdings, Inc.INDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials